Accessing a new class of targets
"Targets lost" in tumor cells
Our unique approach to tumor cell targeted killing has the potential to create breakthrough therapies to treat most cancer patients by identifying targets that unequivocally distinguish tumor from normal cells. We do this by focusing on targets that are irreversibly lost in tumor cells by employing a much more powerful version of the mechanism used by natural killer cells. Loss of chromosomal material leads to hemizygosity of large regions of the genome. This provides the potential to address a large patient population (e.g., in the US more than 300,000 cancer patient deaths per year).
We engineer T cells that target the loss of genetic material, enabling the selective killing of tumor cells. A2 has a platform to leverage “targets lost” using an engineered T cell with an activator and blocker. Tumor cells lack the blocker target due to the permanent loss of genetic material, enabling the T cell to selectively kill tumor cells. Our platform can produce many products across all solid tumors using various activator/blocker combinations.
A component of the platform, the HuTARGTM technology, is licensed from Innovative Targeting Solutions (Vancouver, British Columbia).
Pipeline focused on solid tumor targets
In addition to discovery research, we are planning to innovate in manufacturing. Our autologous cell manufacturing facility will be operational in 2021 with technology scalable for commercial launch.
We aspire to increase speed to patients and reduce cost of goods by advancing the technology and leveraging our cell therapy manufacturing expertise.